RxDoctor Payments Data

Lacey West

Family · Abilene, TXNPI 1154018737

Payments from drug & device makers

$758in general payments, 2019–2025

Across 32 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$326
  • GSK$175
  • Verona Pharma, Inc.$77
  • Boehringer Ingelheim$66
  • Sanofi$62
  • Insmed, Inc.$31
  • plus $21 from 1 others

What the payments were for

  • Food & beverage$758100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$758 in reported general payments places this provider in the 60th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$56,058
Medicare patients
402
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter219$152,346
Breztri AerosphereBudesonide/Glycopyr/Formoterol119$80,876
Breo ElliptaFluticasone/Vilanterol50$18,528
Bevespi AerosphereGlycopyrrolate/Formoterol Fum33$16,986
Spiriva RespimatTiotropium Bromide32$16,871
Stiolto RespimatTiotropium Br/Olodaterol Hcl26$15,962
Combivent RespimatIpratropium/Albuterol Sulfate27$13,518
Fluticasone-SalmeterolFluticasone Propion/Salmeterol94$10,284
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$8,299
Incruse ElliptaUmeclidinium Bromide18$6,318
SymbicortBudesonide/Formoterol Fumarate26$6,060
Wixela InhubFluticasone Propion/Salmeterol49$4,629
Advair DiskusFluticasone Propion/Salmeterol16$3,388
Advair HfaFluticasone Propion/Salmeterol12$3,279
Albuterol Sulfate HfaAlbuterol Sulfate118$2,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$175$185,491301 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$326$103,923178 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$66$46,35185 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 15,456 family providers in Texas.

Other family in Abilene

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →